Pattern Group Inc. Series A Common Stock
PTRN
$20.95
+2.90%
Pattern Group Inc. is an e-commerce accelerator that combines a proprietary technology platform, data science, and in-house category experts to help consumer brands grow across online marketplaces, operating primarily by acquiring inventory from brand partners and reselling to consumers with full control over content, pricing, logistics, and customer service. The company occupies a differentiated position in the Communication Services/Advertising Agencies universe as a hybrid operator-agency — part marketplace retailer, part outsourced e-commerce operating partner — with roughly 2,300 employees and a brand portfolio spanning health and wellness, beauty, home and lifestyle, pet, sports and outdoors, and consumer electronics, overwhelmingly concentrated in the United States. The current investor narrative centers on Pattern's post-IPO execution story: a September 2025 Nasdaq listing, a swing from a large Q3 2025 loss to consistent GAAP profitability through 2026, and revenue growth that re-accelerated to roughly 38% year-over-year in the latest quarter. Debate now hinges on whether that growth is durable and margin-accretive, particularly given a sharp July-to-October drawdown, a recent Jefferies downgrade to Hold, and a valuation that screens cheap on forward earnings but rich on EBITDA multiples.…
PTRN
Pattern Group Inc. Series A Common Stock
$20.95
Investment Opinion: Should I buy PTRN Today?
Rating: Buy (speculative, small-position). The core thesis is that PTRN is a profitable, nearly debt-free, 38.5% revenue grower trading at roughly 11.2x forward consensus EPS ($1.77 against the $19.82 price) with a PEG of 0.47, while four of five named analysts (JP Morgan Overweight, Needham Buy, Evercore ISI Outperform, Keybanc Overweight) carry Buy-equivalent ratings reiterated as recently as November 2-5, 2026. The market is pricing skepticism about margin durability that the last three quarters of GAAP profitability do not support, creating an asymmetric setup if operating leverage holds.
The supporting evidence is concrete: Q3 2026 revenue of $885.85 million grew 38.49% YoY and has risen sequentially every quarter from $723.10 million in Q4 2025 to $773.73 million, $876.77 million, and $885.85 million; net income swung from a $222.99 million loss in Q3 2025 (driven by a $281.66 million non-cash charge) to $32.07 million in Q3 2026; operating margin improved from 3.60% in Q4 2025 to 4.23% in Q3 2026; free cash flow is positive at $105.89 million TTM with capex of only ~$10-11 million per quarter; and the balance sheet carries debt-to-equity of 0.053, a current ratio of 2.34, and $351.69 million in cash. The 0.81x PS ratio is extraordinarily low for a 38% grower, though the 111.0x EV/EBITDA and 20.5x price-to-cash-flow multiples correctly flag the inventory-heavy, low-margin economics.
The biggest risks that could invalidate the thesis are (1) margin stall — trailing operating margin is just 1.02% and net margin 0.65%, so if operating margin fails to hold above the 4.23% Q3 level the forward earnings bridge from 23.8x historical to ~11x forward PE collapses; (2) growth deceleration below 30% against analyst 2027 revenue of $7.33 billion versus a ~$3.4 billion annualized Q3 run-rate; and (3) valuation/volatility risk from thin two-analyst coverage and a -47.88% max drawdown. This Buy would downgrade to Hold if gross margin breaks below the 42.9% floor of its five-quarter band or operating margin slips back under 3.5%, and would upgrade in conviction if Q4 operating margin exceeds 5% with revenue growth above 35%. Verdict: undervalued relative to its own short history (PS compressed from 5.09x in Q1 2025 to 0.81x) and cheap on forward earnings, but fairly-to-richly valued on EBITDA and cash flow — a genuine value-with-growth setup rather than a deep-value bargain.
Sign up to view all
PTRN 12-Month Price Forecast
The forward view is constructive but not high-conviction: PTRN offers 38.49% revenue growth and a decisive swing to GAAP profitability at roughly 11.2x forward EPS, a combination that screens cheap against its own 23.8x historical multiple and its 0.47 PEG. The base case (50% probability) assumes growth moderates into the high-20s to low-30s percent range with operating margin stabilizing near 4%-4.5%, supporting a $21.50-$24.50 range as the multiple re-rates modestly from ~11.2x. The bull case (30%) requires operating margin to push toward the 5.1% Q1 2026 level and reclaim the $28-$29.40 July peak, while the bear case (20%) hinges on gross margin breaking its 42.9% floor and a retest of the $15.87 October low. I would upgrade to high confidence if Q4 2026 shows operating margin above 5% with revenue growth above 35%, and downgrade to neutral if gross margin falls below 42.9% or free cash flow turns negative on working-capital swings.
Wall Street consensus
Coverage is thin, with only two analysts contributing EPS and revenue estimates, though institutional ratings show broader engagement: JP Morgan (Overweight), Needham (Buy), Evercore ISI (Outperform), and Keybanc (Overweight) have all reiterated positive ratings as recently as November 2-5, 2026, while Jefferies downgraded to Hold from Buy on July 14, 2026. The consensus leans clearly bullish — four of five named firms carry Buy-equivalent ratings — but a specific average price target is not available in the provided data, so implied upside cannot be calculated. The pattern of repeated reiterations rather than fresh initiations suggests analysts are maintaining existing theses rather than adding conviction.
Estimate dispersion is tight, signaling reasonable confidence in near-term numbers: EPS estimates range from $1.71 to $1.82 around a $1.77 average (a spread of just ~6%), and revenue estimates range from $7.15 billion to $7.47 billion around a $7.33 billion average (a spread of ~4.5%). The high end implies roughly 4.5% more revenue than the low end, consistent with modest differences in marketplace share assumptions rather than divergent bull/bear theses. The key signal is the Jefferies downgrade to Hold in July — coinciding with the stock's peak near $29 — which suggests at least one analyst views the risk/reward as balanced after the run-up; the subsequent 45% drawdown has arguably restored some of that upside, but with only two analysts publishing targets, price discovery remains inefficient and the stock is likely to stay more volatile than better-covered peers.
Bulls vs Bears: PTRN Investment Factors
The bull case currently has stronger evidence: revenue is re-accelerating at 38.5% YoY, the company has swung decisively to GAAP profitability with improving operating margins, the balance sheet is nearly debt-free with $351.69 million in cash, and the stock trades at roughly 11.2x forward consensus EPS with four of five named analysts at Buy-equivalent ratings. The bear case rests less on fundamentals than on valuation mechanics and volatility — a 111x EV/EBITDA multiple, a 3.62% net margin that leaves little room for error, and a -47.88% max drawdown that underscores how violently the stock can re-rate. The single most important tension is margin durability: the market is paying 23.8x historical earnings but only ~11x forward EPS, implying it expects margins to expand materially as revenue scales; if operating leverage stalls near the current 4.23% level, the forward earnings bridge collapses and the stock would likely retest its October low. Conversely, if gross margin holds above 43% and operating margin pushes toward the 5%+ levels seen in Q1 2026, the current valuation would look meaningfully undervalued.
Bullish
- Revenue re-accelerating at 38.5% YoY: Q3 2026 revenue of $885.85 million grew 38.49% year-over-year versus $639.66 million, and the sequential trajectory has been consistently upward from $773.73 million in Q1 to $876.77 million in Q2. The roughly $112 million of sequential revenue added from Q1 2025 to Q3 2026 confirms genuine scale expansion rather than a one-off comp effect.
- Decisive swing to GAAP profitability: Q3 2026 net income was $32.07 million (3.62% net margin) versus a $222.99 million loss in Q3 2025 that was driven largely by a $281.66 million non-cash charge. Operating margin has improved from 3.60% in Q4 2025 to 4.23% in Q3 2026, and net margin rose from 3.14% in Q2 to 3.62% in Q3, showing real operating leverage.
- Fortress balance sheet with self-funding growth: Debt-to-equity is just 0.053, the current ratio is 2.34, and cash stood at $351.69 million with negligible interest expense. Free cash flow is positive at $105.89 million TTM and capex is light at roughly $10-11 million per quarter, meaning the business largely self-funds its expansion.
- Cheap on forward earnings: Using the analyst consensus EPS of $1.77 against the $19.82 price implies a forward PE of roughly 11.2x, versus the Q3 2026 historical PE of 23.8x on annualized earnings. The PEG of 0.47 and PS of 0.81x suggest the market is pricing considerable skepticism relative to the 38% growth rate.
Bearish
- Extreme EV/EBITDA multiple of 111x: Despite a low 0.81x PS ratio, PTRN trades at 111.0x EV/EBITDA and 20.5x price-to-cash-flow, a steep premium that reflects the inventory-heavy, low-margin nature of the model. The divergence between the cheap sales multiple and rich EBITDA multiple means headline valuation screens can be misleading.
- Razor-thin net margins limit error tolerance: Net margin is only 3.62% and the full-year net margin reads 0.65%, with operating margin at just 1.02% on a trailing basis. Gross margin has been remarkably stable in a 42.9%-43.8% band across five quarters, suggesting limited room for further margin expansion to justify the forward earnings multiple.
- Violent drawdown and high realized volatility: The stock suffered a -47.88% max drawdown, falling from a July peak of $29.40 to an October trough of $15.87 — a roughly 46% decline in about three months. The 22% rally in under three weeks from $16.19 to $19.82 implies realized volatility well in excess of the market, arguing for smaller position sizing.
- Thin coverage and inefficient price discovery: Only two analysts contribute EPS and revenue estimates, and no consensus average price target is available, so implied upside cannot be calculated. The Jefferies downgrade to Hold on July 14, 2026 near the $29 peak suggests at least one analyst viewed risk/reward as balanced after the run-up, and the stock is likely to stay more volatile than better-covered peers.
PTRN Technical Analysis
PTRN is in a choppy, range-bound recovery phase rather than a clean uptrend. The stock is up 11.98% over the trailing year and an outsized 72.35% year-to-date, but that YTD figure is measured from a depressed post-IPO base; the current price of $19.82 sits roughly 67% of the way through its 52-week range, well below the July peak near $29.40 and well above the October trough around $15.87. That mid-to-upper range positioning signals recovering momentum rather than either overextension or a falling knife, though the -47.88% max drawdown underscores how violent the round trip has been. Relative strength tells the same story: PTRN has beaten SPY by 62.38 percentage points YTD and 21.66 points over six months, but trails by 8.83 points over three months.
Short-term momentum has clearly turned constructive and is diverging positively from the intermediate trend. The stock is up 7.60% over the past month versus a -3.68% decline for SPY, a relative strength spread of +11.28 points, and it has rallied from $16.19 on October 23 to $19.82 on November 10 — a roughly 22% move in under three weeks, including a +2.01% session on the latest close. That contrasts sharply with the -11.75% three-month change, meaning the September-October leg down (from ~$20.41 on September 22 to $15.87 on October 26) has been substantially retraced. The pattern — strong 1-month, weak 3-month, strong 1-year — is characteristic of a mean-reversion bounce within a broader consolidation rather than a confirmed new uptrend, and the recent surge into the mid-$19s likely leaves the stock short-term extended ahead of resistance.
Key technical levels are well defined. Resistance sits at the July high of $29.40, with an intermediate ceiling around $22.90-$24.45 where the stock repeatedly stalled in late July and August; a decisive break above $24 would signal the consolidation has resolved higher and likely re-open the $29 area. Support rests at the October low of $15.87, with secondary support near $16.20-$16.60 where the stock based in late October; a breakdown below $15.87 would invalidate the recovery and target new post-IPO lows. Beta is not available in the provided data, but the -47.88% max drawdown and the 22% three-week rally imply high realized volatility well in excess of the market, which argues for smaller position sizing and wider stops.
Beta
—
—
Max Drawdown
-47.9%
Largest decline past year
52-Week Range
—
Price range past year
Annual Return
+15.2%
Cumulative gain past year
| Period | PTRN Return | S&P 500 |
|---|---|---|
| 1m | +21.8% | -2.7% |
| 3m | -2.3% | -2.5% |
| 6m | +26.9% | +2.4% |
| 1y | +15.2% | +10.8% |
| ytd | +82.2% | +11.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
PTRN Fundamental Analysis
Revenue growth is strong and re-accelerating. Q3 2026 revenue of $885.85 million grew 38.49% year-over-year versus $639.66 million in Q3 2025, and the sequential trajectory has been consistently upward: $773.73 million in Q1 2026, $876.77 million in Q2, and $885.85 million in Q3, following $723.10 million in Q4 2025 and $540.41 million in Q1 2025. The year-over-year comparison is flattered by a weak prior-year base, but the absolute dollar progression — roughly $112 million of sequential revenue added from Q1 2025 to Q3 2026 — confirms genuine scale expansion rather than a one-off comp effect. With two analysts modeling average 2027 revenue of $7.33 billion against a roughly $3.4 billion annualized Q3 run-rate, the market is implicitly assuming growth remains well above 30%, which is the central pillar of the investment case.
Profitability has inflected decisively. Q3 2026 net income was $32.07 million (a 3.62% net margin) on gross profit of $386.68 million, a 43.65% gross margin, versus a net loss of $222.99 million in Q3 2025 that was driven largely by a $281.66 million non-cash charge. Gross margin has been remarkably stable in a 42.9%-43.8% band across the last five quarters, while operating margin has improved from 3.60% in Q4 2025 to 4.23% in Q3 2026 and net margin from 3.14% in Q2 2026 to 3.62% in Q3. The margin structure — low-teens operating margins at best, thin net margins — is typical of an inventory-holding e-commerce operator rather than a high-margin ad agency, so the key question is whether operating leverage can push margins meaningfully higher as revenue scales.
The balance sheet is a clear strength. Debt-to-equity is just 0.053, the current ratio is 2.34, and cash stood at $351.69 million at quarter-end against negligible interest expense, giving the company ample liquidity. Free cash flow is positive but lumpy: $105.89 million TTM, with quarterly FCF of $63.32 million in Q1 2026, $3.76 million in Q2, and $35.60 million in Q3, reflecting working-capital swings (inventory and receivables) inherent to the model. ROE is modest at 2.80%, held down by a large post-IPO equity base, and capex is light at roughly $10-11 million per quarter, meaning the business largely self-funds growth — a meaningful de-risking factor.
Quarterly Revenue
$885847000.0B
2026-09
Revenue YoY Growth
+38.5%
YoY Comparison
Gross Margin
43.6%
Latest Quarter
Free Cash Flow
$105889000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is PTRN Overvalued?
Because trailing net income is positive ($32.07 million in Q3 2026), the PE ratio is the appropriate primary metric, but the trailing figure of -12.97x is distorted by the prior-year loss and is not meaningful; the more relevant read is the forward PE of 0.47x, which is almost certainly a data artifact (it appears to equal the PEG ratio) rather than a genuine multiple. Using the analyst consensus EPS of $1.77 against the $19.82 price implies a forward PE of roughly 11.2x, while the Q3 2026 historical PE of 23.8x on annualized earnings suggests the market is pricing in substantial forward earnings growth. The enormous gap between trailing and forward earnings power implies the market expects margins to expand materially as revenue scales.
On sales, PTRN trades at just 0.81x trailing PS — extraordinarily low for a company growing revenue 38% — but this reflects the low-margin, inventory-heavy nature of the model rather than deep undervaluation. The more telling multiples are EV/EBITDA of 111.0x and price-to-cash-flow of 20.5x, alongside a P/B of 3.50x and PEG of 0.47. Industry-average multiples for Advertising Agencies are not provided in the data, so a precise premium/discount spread cannot be quantified; qualitatively, a 0.81x PS is a steep discount to typical agency comps (often 1-3x), but the 111x EV/EBITDA is a steep premium, and the divergence simply reflects the accounting reality that Pattern books gross revenue on inventory it owns.
Against its own short history, valuation has compressed sharply. PS has fallen from 5.09x in Q1 2025 and 3.43x in Q3 2026 to 0.81x today, and P/B from 6.84x in Q1 2025 to 3.50x, as the share count and equity base grew post-IPO while the stock de-rated. The Q3 2026 historical PE of 23.8x versus the current implied forward PE of ~11x suggests the market is now pricing considerably more modest expectations than it did earlier in 2026 — a setup that offers upside if growth holds but reflects real skepticism about margin durability.
PE
-13.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 18x~59x
vs. Industry Avg
25.7x
Industry PE ~25.7x*
EV/EBITDA
111.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the thin-margin, inventory-heavy model. Net margin is just 3.62% in Q3 2026 and 0.65% on a trailing basis, with operating margin at 1.02% trailing and 4.23% in the latest quarter — a structure that leaves little buffer if gross margin (stable at 42.9%-43.8% across five quarters) compresses even modestly. Free cash flow is lumpy, swinging from $63.32 million in Q1 2026 to $3.76 million in Q2 and $35.60 million in Q3 as inventory and receivables absorb working capital, and ROE is a modest 2.80% held down by the large post-IPO equity base. The company's dependence on continued above-30% growth to justify its forward earnings multiple means any deceleration would be punished disproportionately, and revenue is overwhelmingly concentrated in the United States, adding geographic concentration risk.
Market and competitive risks are dominated by valuation compression and coverage thinness. The stock trades at 111.0x EV/EBITDA and 20.5x price-to-cash-flow despite a 0.81x PS ratio, and its PS multiple has already compressed from 5.09x in Q1 2025 to 0.81x today as the share count and equity base grew post-IPO — evidence that de-rating is an active, realized risk rather than a theoretical one. Beta is not available in the provided data, but the -47.88% max drawdown and the 22% three-week rally imply high realized volatility well in excess of the market, and the stock trails SPY by 8.83 points over three months despite beating it by 62.38 points YTD. Only two analysts publish estimates, so price discovery is inefficient, and the Jefferies downgrade to Hold in July 2026 near the $29 peak shows how quickly sentiment can shift after a run-up.
In a worst-case scenario, revenue growth decelerates below 30% as marketplace share assumptions prove optimistic, gross margin slips below the 42.9% floor of its five-quarter band, and the forward earnings bridge from 23.8x historical to ~11x forward PE fails to materialize — triggering analyst estimate cuts and a re-rating toward the low end of its trading history. The realistic downside is a retest of the October 26, 2026 low of $15.87, which from the current $19.82 price represents roughly -20%, and a break below that level would invalidate the recovery and target new post-IPO lows. In a more severe scenario mirroring the full -47.88% max drawdown from the July peak, an investor could lose approximately 45-48% from current levels, underscoring the need for position sizing discipline.
FAQ
Ranked by severity: first, margin durability — trailing operating margin is only 1.02% and net margin 0.65%, so a gross margin slip below the 42.9% floor of its five-quarter band would quickly erode the thin profit base and invalidate the ~11x forward multiple. Second, valuation mechanics — EV/EBITDA of 111.0x and price-to-cash-flow of 20.5x leave the stock exposed to multiple compression, and PS has already collapsed from 5.09x in Q1 2025 to 0.81x, showing de-rating is a realized rather than theoretical risk. Third, volatility and coverage — the -47.88% max drawdown from the July peak of $29.40 to the October low of $15.87, combined with only two analysts publishing estimates, means inefficient price discovery and violent swings; the Jefferies downgrade to Hold in July 2026 near the peak shows how fast sentiment flips. Fourth, cash flow lumpiness — free cash flow swung from $63.32 million in Q1 2026 to $3.76 million in Q2 on working-capital swings, and revenue is overwhelmingly concentrated in the United States.
The scenario framework assigns a 50% probability to the base case of $21.50-$24.50, a 30% probability to the bull case of $28.00-$29.40, and a 20% probability to the bear case of $15.87-$17.00. The base case is most likely and assumes revenue growth moderates into the high-20s to low-30s percent range, gross margin stays within its 42.9%-43.8% band, operating margin holds between 4.0% and 4.5%, and consensus EPS of $1.77 is met within the tight $1.71-$1.82 estimate range, allowing a modest re-rating from ~11.2x toward 12-14x. The bull case requires operating margin to push toward the 5.1% Q1 2026 level and reclaim the July peak, while the bear case hinges on gross margin breaking its floor and a retest of the $15.87 October low. Note that no consensus average price target is available from the two contributing analysts, so these ranges are anchored to the stock's own trading levels and valuation rather than published targets.
The answer depends heavily on which multiple you trust, and the divergence is the story. On sales, PTRN is strikingly cheap at 0.81x PS for a 38% grower, and on forward earnings it screens at roughly 11.2x the $1.77 consensus EPS against a 23.8x historical PE, with a PEG of 0.47. But the inventory-holding model means those headline figures flatter the economics: EV/EBITDA is 111.0x and price-to-cash-flow is 20.5x, both steep. Against its own short history, valuation has compressed hard — PS has fallen from 5.09x in Q1 2025 to 0.81x today and P/B from 6.84x to 3.50x as the post-IPO equity base grew and the stock de-rated. The market is therefore pricing modest expectations on margins and durability; if operating margin holds near 4.2% and growth stays above 30%, the stock looks undervalued on forward earnings, but on EBITDA and cash flow it is fairly-to-richly valued.
On a risk/reward basis the setup is favorable but not clean. At $19.82, PTRN trades at roughly 11.2x the $1.77 consensus EPS while growing revenue 38.49% year-over-year and generating $105.89 million in trailing free cash flow, and four of five named analysts (JP Morgan, Needham, Evercore ISI, Keybanc) carry Buy-equivalent ratings reiterated as recently as November 2-5, 2026. The biggest downside risk is a margin stall: trailing operating margin is just 1.02%, so if the 4.23% Q3 level does not hold, the forward earnings bridge collapses and the stock could retest its October 26, 2026 low of $15.87, roughly -20% from here. A severe repeat of the -47.88% max drawdown would imply losses of 45-48%. It is a reasonable buy for risk-tolerant investors with a 12-24 month horizon who size it as a small position, but not for capital-preservation portfolios or anyone unable to tolerate a 20%+ drawdown.
PTRN is better suited to a medium-to-long-term hold than to short-term trading, but only with position sizing that respects its volatility. It pays no dividend (payout ratio of 0), so total return depends entirely on earnings growth and multiple re-rating, and its earnings visibility is improving but still short — the company listed on Nasdaq only in September 2025, giving roughly a year of public financials. The -47.88% max drawdown and the 22% rally from $16.19 to $19.82 in under three weeks imply realized volatility well above the market, which makes short-term trading a timing gamble against thin two-analyst coverage. A concrete minimum holding period of 12-24 months allows the Q4 2026 and full-year 2027 results to validate or refute the margin-expansion thesis underlying the ~11x forward multiple. Investors should treat it as a small satellite growth position rather than a core allocation.